<DOC>
	<DOCNO>NCT01666314</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , multiregional Phase1/2 study characterize pharmacokinetic pharmacodynamic response orteronel administer concomitantly prednisone Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer</brief_summary>
	<brief_title>Study Japan Ex-Japan Characterize Pharmacokinetic Pharmacodynamic Response Orteronel ( TAK-700 ) Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>The drug test study call orteronel . Orteronel test treat adult male adenocarcinoma prostate . This study look pharmacokinetics ( drug move body ) pharmacodynamics ( drug effect body ) people take orteronel addition prednisone . The study enroll approximately 144 patient . Participants randomly assign ( chance , like flip coin ) one eight treatment group ( 4 Japan , 4 Ex-Japan ) remain undisclosed patient study doctor study ( unless urgent medical need ) . In Japan : Participants randomize ratio 2:1:2:1 : - 200 mg orteronel Placebo-matching orteronel [ ( dummy inactive pill ) - tablet look like study drug active ingredient ] twice daily ( BID ) + prednisone - 300 mg orteronel , Placebo-matching orteronel , BID + prednisone Ex-Japan Participants randomize ratio 2:1:2:1 : - 200 mg orteronel Placebo-matching orteronel , BID Cycle 1 + prednisone - 400 mg orteronel , Placebo-matching orteronel , BID Cycle 1 + Prednisone Patients initially randomize placebo receive 4 week placebo 12 week active treatment orteronel enter follow-up period treatment period . Patients initially randomize orteronel receive 16 week treatment enter follow-up treatment period . This multi-centre trial conduct worldwide . The overall time participate study approximately 2.5 year . Participants make multiple visit clinic final visit 30 40 day receive last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Male patient 18 year old Voluntary write consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care Histologically cytologically confirm diagnosis prostate adenocarcinoma Prior surgical castration concurrent use agent medical castration [ e.g.Gonadotropinreleasing hormone ( GnRH ) analogue ] ProstateSpecific Antigen ( PSA ) ≥ 2 ng/mL screen Progressive disease base PSA and/or radiographic criterion Prior therapy orteronel , ketoconazole , aminoglutethimide , abiraterone . Known hypersensitivity compound related orteronel , orteronel excipients , prednisone ( commercially available equivalent ) , GnRH analogue . All antiandrogen therapy ( include bicalutamide ) exclude within 4 week first dose study drug . Any therapies prostate cancer , GnRH analogue therapy , progesterone , medroxyprogesterone , progestin ( megesterol ) , 5 alpha reductase inhibitor ( eg , finasteride dutasteride ) , must discontinue 2 week first dose study drug . Continuous daily use oral prednisone ( commercially available equivalent ) , oral dexamethasone , systemic corticosteroid 2 week within 3 month screen ( inhale , nasal , local steroid [ eg , joint injection ] allow ) . Prior chemotherapy prostate cancer , exception neoadjuvant/adjuvant therapy part initial primary treatment local disease complete 2 year screen . Please note additional inclusion exclusion criterion . The study center determine meet criterion . Site personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , site personnel explain reason</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>castrate resistant prostate cancer ,</keyword>
	<keyword>CRPC ,</keyword>
	<keyword>orteronel ,</keyword>
	<keyword>TAK-700</keyword>
</DOC>